Spero Therapeutics, Inc. (SPRO) is a Biotechnology company in the Healthcare sector, currently trading at $2.78. It has a SharesGrow Score of 61/100, indicating a above average investment profile with 2 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of SPRO = $7.22 (+159.7% from the current price, the stock appears undervalued).
Valuation: SPRO trades at a trailing Price-to-Earnings (P/E) of 17.9 (S&P 500 average ~25).
Financials: revenue is $60M, +48.4%/yr average growth. Net income is $9M, growing at -46.9%/yr. Net profit margin is 14.4% (healthy). Gross margin is 100% (+3.2 pp trend).
Balance sheet: total debt is $3M against $59M equity (Debt-to-Equity (D/E) ratio 0.05, conservative). Current ratio is 7.59 (strong liquidity). Debt-to-assets is 4.2%. Total assets: $69M.
Analyst outlook: 6 / 13 analysts rate SPRO as buy (46%) — mixed sentiment.
SharesGrow 7-Criteria breakdown: Value 93/100 (Pass), Growth 58/100 (Partial), Past 50/100 (Partial), Health 100/100 (Pass), Moat 50/100 (Partial), Future 20/100 (Fail), Income 55/100 (Partial).
